Skip to main content

Table 2 Predicted DDI types of drug pairs

From: Novel deep learning model for more accurate prediction of drug-drug interaction effects

Drug A

Drug B

DDI type (Drugbank v5.1.1)a

Score (Drugbank v5.1.1)

DDI type (new prediction)a

Score (new prediction)

Reference

Amodiaquine

Pyrimethamine

100

0.999999762

86

0.999997854

DrugBank v 5.1.2

Amodiaquine

Cholecalciferol

100

0.99999392

86

0.996211529

DrugBank v 5.1.2

Betrixaban

Rivaroxaban

76

0.518932223

18

0.989234567

DrugBank v 5.1.2

Disopyramide

Asenapine

24

0.775597036

72

0.984019518

https://www.pdr.net

Nefazodone

Amoxapine

19

0.581683695

56

0.907319307

https://online.epocrates.com

Ulipristal

Pentobarbital

99

0.999979138

104

0.902777851

https://www.pdr.net

Fingolimod

Dronedarone

22

0.547105849

14

0.881702363

[21]

Trazodone

Methylene blue

56

0.697363019

96

0.879396319

https://www.pdr.net

Fluorouracil

Metronidazole

100

0.782166064

102

0.864007413

https://www.drugs.com

Tacrolimus

Escitalopram

86

0.511624634

14

0.851550758

[22, 21]

Tacrolimus

Citalopram

86

0.511636794

14

0.851546466

[22, 23]

Methadone

Escitalopram

86

0.537029743

14

0.849954724

[22, 21]

  1. a 14: DRUG_A may increase the QTc-prolonging activities of DRUG_B
  2. 18: DRUG_A may increase the anticoagulant activities of DRUG_B
  3. 19: DRUG_A may increase the antihypertensive activities of DRUG_B
  4. 22: DRUG_A may increase the arrhythmogenic activities of DRUG_B
  5. 24: DRUG_A may increase the bradycardic activities of DRUG_B
  6. 56: DRUG_A may increase the serotonergic activities of DRUG_B
  7. 72: The risk or severity of QTc prolongation can be increased when DRUG_A is combined with DRUG_B
  8. 76: The risk or severity of bleeding can be increased when DRUG_A is combined with DRUG_B
  9. 86: The risk or severity of hypotension can be increased when DRUG_A is combined with DRUG_B
  10. 96: The risk or severity of serotonin syndrome can be increased when DRUG_A is combined with DRUG_B
  11. 99: The serum concentration of DRUG_A can be decreased when it is combined with DRUG_B
  12. 100: The serum concentration of DRUG_A can be increased when it is combined with DRUG_B
  13. 102: The serum concentration of the active metabolites of DRUG_A can be increased when DRUG_A is used in combination with DRUG_B
  14. 104: The therapeutic efficacy of DRUG_A can be decreased when used in combination with DRUG_B